Thursday, November 21, 2013
The inability to generate fully undifferentiated human
induced pluripotent stem cells in vitro has dogged the development of
stem cell-based platforms because the residual lineage bias of the cells most
likely contributes to the inefficiency and inconsistency of current
differentiation protocols. An Israeli team thinks it has solved the problem
with the optimization of a small molecule and cytokine cocktail capable of
maintaining human cells in a more fully undifferentiated state.1
In vitro applications
Martz, L. SciBX 6(45); doi:10.1038/scibx.2013.1282 Published online
Nov. 21, 2013
1. Gafni, O. et al.
Nature; published online Oct. 30, 2013; doi:10.1038/nature12745 Contact:
Jacob H. Hanna, Weizmann Institute of Science, Rehovot, Israel e-mail: firstname.lastname@example.org
Contact: Noa Novershtern, same affiliation as above e-mail: email@example.com
Contact: Rada Massarwa, same affiliation as above e-mail: firstname.lastname@example.org
2. Narsinh, K.H. et al.
J. Clin. Invest. 121, 1217-1221 (2011)
3. Hanna, J. et al.
Proc. Natl. Acad. Sci. USA 107, 9222-9227 (2010)
4. Tesar, P.J. et al.
Nature 448, 196-199 (2007)
AND INSTITUTIONS MENTIONED
Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica,
Cellular Dynamics International Inc. (NASDAQ: ICEL), Madison, Wis.
Gladstone Institute of Cardiovascular Disease, San Francisco, Calif.
Harvard Medical School, Boston, Mass.
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Tel Aviv University Sackler Faculty of Medicine, Tel Aviv, Israel
University of California, San Francisco, Calif.
Weizmann Institute of Science, Rehovot, Israel